- Home
- KTTA vs SNPX Comparison
KTTA vs SNPX Comparison
Compare KTTA & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- SNPX
- Stock Information
- Founded
- KTTA 2020
- SNPX 2012
- Country
- KTTA United States
- SNPX United States
- Employees
- KTTA N/A
- SNPX N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- KTTA Health Care
- SNPX Health Care
- Exchange
- KTTA Nasdaq
- SNPX Nasdaq
- Market Cap
- KTTA 3.2M
- SNPX 3.7M
- IPO Year
- KTTA 2021
- SNPX N/A
- Fundamental
- Price
- KTTA $2.48
- SNPX $3.30
- Analyst Decision
- KTTA
- SNPX Strong Buy
- Analyst Count
- KTTA 0
- SNPX 1
- Target Price
- KTTA N/A
- SNPX $14.00
- AVG Volume (30 Days)
- KTTA 43.9K
- SNPX 33.7K
- Earning Date
- KTTA 11-13-2024
- SNPX 11-12-2024
- Dividend Yield
- KTTA N/A
- SNPX N/A
- EPS Growth
- KTTA N/A
- SNPX N/A
- EPS
- KTTA N/A
- SNPX N/A
- Revenue
- KTTA N/A
- SNPX N/A
- Revenue This Year
- KTTA N/A
- SNPX N/A
- Revenue Next Year
- KTTA N/A
- SNPX N/A
- P/E Ratio
- KTTA N/A
- SNPX N/A
- Revenue Growth
- KTTA N/A
- SNPX N/A
- 52 Week Low
- KTTA $2.20
- SNPX $2.32
- 52 Week High
- KTTA $9.25
- SNPX $7.23
- Technical
- Relative Strength Index (RSI)
- KTTA 38.84
- SNPX 51.02
- Support Level
- KTTA $2.20
- SNPX $3.10
- Resistance Level
- KTTA $2.61
- SNPX $3.58
- Average True Range (ATR)
- KTTA 0.28
- SNPX 0.33
- MACD
- KTTA -0.03
- SNPX -0.03
- Stochastic Oscillator
- KTTA 24.35
- SNPX 32.04
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.